offline
Eli Lilly and Company
| 07.01.2019, 21:48 (Dieser Beitrag wurde zuletzt bearbeitet: 29.03.2019, 21:29 von Ca$hmandt.)
Eli Lilly to Buy Loxo Oncology for $8 Billion
(Bloomberg) -- Eli Lilly & Co. will acquire Loxo Oncology Inc. for about $8 billion in cash, the second multibillion-dollar cancer deal of the year by a major U.S. pharmaceutical company.
The purchase is Indianapolis-based Lilly’s biggest takeover ever, according to data compiled by Bloomberg. Loxo holders will get $235 per share in cash, the companies said in a statement Monday. The Stamford, Connecticut-based biotechnology company is developing cancer treatments that target a tumor’s genetic markers regardless of where in the body they’re located.
Lilly is offering a rich premium -- 68 percent above Loxo’s closing stock price Friday and far above Loxo’s previous all-time high of $189.96, reached in July 2018. It’s another sign that drugmakers are willing to pay rich prices for assets after Bristol-Myers Squibb Co. and Celgene Corp. announced a $74 billion cash-and-stock deal last week.
Loxo shares rose 66 percent to $232.62 at 9:50 a.m. in New York. Lilly shares fell 1.5 percent to $112.95.
...
https://finance.yahoo.com/news/eli-lilly...25116.html
![[Bild: LLYc1dl1445.png]](https://finviz.com/publish/010719/LLYc1dl1445.png)
![[Bild: LOXOc0wl1448.png]](https://finviz.com/publish/010719/LOXOc0wl1448.png)
(Bloomberg) -- Eli Lilly & Co. will acquire Loxo Oncology Inc. for about $8 billion in cash, the second multibillion-dollar cancer deal of the year by a major U.S. pharmaceutical company.
The purchase is Indianapolis-based Lilly’s biggest takeover ever, according to data compiled by Bloomberg. Loxo holders will get $235 per share in cash, the companies said in a statement Monday. The Stamford, Connecticut-based biotechnology company is developing cancer treatments that target a tumor’s genetic markers regardless of where in the body they’re located.
Lilly is offering a rich premium -- 68 percent above Loxo’s closing stock price Friday and far above Loxo’s previous all-time high of $189.96, reached in July 2018. It’s another sign that drugmakers are willing to pay rich prices for assets after Bristol-Myers Squibb Co. and Celgene Corp. announced a $74 billion cash-and-stock deal last week.
Loxo shares rose 66 percent to $232.62 at 9:50 a.m. in New York. Lilly shares fell 1.5 percent to $112.95.
...
https://finance.yahoo.com/news/eli-lilly...25116.html
